Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium

B. Maecker, M. S. Von Bergwelt-Baildon, Karen Anderson, R. H. Vonderheide, J. L. Schultze

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The disclosure of the human genome sequence and rapid advances in genomic expression profiling have revolutionized our knowledge about molecular changes in malignant diseases. Rapidly growing gene expression databases and improvements in bioinformatics tools set the stage for new approaches using large-scale molecular information to develop specific therapeutics in cancer. On one hand, the ability to detect clusters of genes differentially expressed in normal and malignant tissue may lead to widely applicable targeting of defined molecular structures. On the other hand, analyzing the 'molecular fingerprint' of an individual tumor raises the possibility of developing customized therapeutics. One approach to use the emerging new datasets for the development of novel therapeutics is to identify genes that are specifically expressed in tumors as targets for immune intervention. This review will focus on the process from in silico analysis of expression databases and screening of potential candidate genes by bioinformatics to the in vitro and in vivo analysis to determine the immunogenicity of candidate tumor antigens. Basic biological principles of 'reverse immunology' as well as technical advantages and difficulties will be addressed.

Original languageEnglish (US)
Pages (from-to)609-619
Number of pages11
JournalCurrent Molecular Medicine
Volume1
Issue number5
StatePublished - 2001
Externally publishedYes

Fingerprint

Immunology
Genomics
Allergy and Immunology
Immunotherapy
Genes
Computational Biology
Bioinformatics
Databases
Tumors
Neoplasms
Aptitude
Disclosure
Dermatoglyphics
Neoplasm Antigens
Human Genome
Multigene Family
Molecular Structure
Computer Simulation
Bioelectric potentials
Therapeutics

ASJC Scopus subject areas

  • Biochemistry

Cite this

Maecker, B., Von Bergwelt-Baildon, M. S., Anderson, K., Vonderheide, R. H., & Schultze, J. L. (2001). Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium. Current Molecular Medicine, 1(5), 609-619.

Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium. / Maecker, B.; Von Bergwelt-Baildon, M. S.; Anderson, Karen; Vonderheide, R. H.; Schultze, J. L.

In: Current Molecular Medicine, Vol. 1, No. 5, 2001, p. 609-619.

Research output: Contribution to journalArticle

Maecker, B, Von Bergwelt-Baildon, MS, Anderson, K, Vonderheide, RH & Schultze, JL 2001, 'Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium', Current Molecular Medicine, vol. 1, no. 5, pp. 609-619.
Maecker B, Von Bergwelt-Baildon MS, Anderson K, Vonderheide RH, Schultze JL. Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium. Current Molecular Medicine. 2001;1(5):609-619.
Maecker, B. ; Von Bergwelt-Baildon, M. S. ; Anderson, Karen ; Vonderheide, R. H. ; Schultze, J. L. / Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium. In: Current Molecular Medicine. 2001 ; Vol. 1, No. 5. pp. 609-619.
@article{acc5650c8e9d4a40b261e34acf155178,
title = "Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium",
abstract = "The disclosure of the human genome sequence and rapid advances in genomic expression profiling have revolutionized our knowledge about molecular changes in malignant diseases. Rapidly growing gene expression databases and improvements in bioinformatics tools set the stage for new approaches using large-scale molecular information to develop specific therapeutics in cancer. On one hand, the ability to detect clusters of genes differentially expressed in normal and malignant tissue may lead to widely applicable targeting of defined molecular structures. On the other hand, analyzing the 'molecular fingerprint' of an individual tumor raises the possibility of developing customized therapeutics. One approach to use the emerging new datasets for the development of novel therapeutics is to identify genes that are specifically expressed in tumors as targets for immune intervention. This review will focus on the process from in silico analysis of expression databases and screening of potential candidate genes by bioinformatics to the in vitro and in vivo analysis to determine the immunogenicity of candidate tumor antigens. Basic biological principles of 'reverse immunology' as well as technical advantages and difficulties will be addressed.",
author = "B. Maecker and {Von Bergwelt-Baildon}, {M. S.} and Karen Anderson and Vonderheide, {R. H.} and Schultze, {J. L.}",
year = "2001",
language = "English (US)",
volume = "1",
pages = "609--619",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium

AU - Maecker, B.

AU - Von Bergwelt-Baildon, M. S.

AU - Anderson, Karen

AU - Vonderheide, R. H.

AU - Schultze, J. L.

PY - 2001

Y1 - 2001

N2 - The disclosure of the human genome sequence and rapid advances in genomic expression profiling have revolutionized our knowledge about molecular changes in malignant diseases. Rapidly growing gene expression databases and improvements in bioinformatics tools set the stage for new approaches using large-scale molecular information to develop specific therapeutics in cancer. On one hand, the ability to detect clusters of genes differentially expressed in normal and malignant tissue may lead to widely applicable targeting of defined molecular structures. On the other hand, analyzing the 'molecular fingerprint' of an individual tumor raises the possibility of developing customized therapeutics. One approach to use the emerging new datasets for the development of novel therapeutics is to identify genes that are specifically expressed in tumors as targets for immune intervention. This review will focus on the process from in silico analysis of expression databases and screening of potential candidate genes by bioinformatics to the in vitro and in vivo analysis to determine the immunogenicity of candidate tumor antigens. Basic biological principles of 'reverse immunology' as well as technical advantages and difficulties will be addressed.

AB - The disclosure of the human genome sequence and rapid advances in genomic expression profiling have revolutionized our knowledge about molecular changes in malignant diseases. Rapidly growing gene expression databases and improvements in bioinformatics tools set the stage for new approaches using large-scale molecular information to develop specific therapeutics in cancer. On one hand, the ability to detect clusters of genes differentially expressed in normal and malignant tissue may lead to widely applicable targeting of defined molecular structures. On the other hand, analyzing the 'molecular fingerprint' of an individual tumor raises the possibility of developing customized therapeutics. One approach to use the emerging new datasets for the development of novel therapeutics is to identify genes that are specifically expressed in tumors as targets for immune intervention. This review will focus on the process from in silico analysis of expression databases and screening of potential candidate genes by bioinformatics to the in vitro and in vivo analysis to determine the immunogenicity of candidate tumor antigens. Basic biological principles of 'reverse immunology' as well as technical advantages and difficulties will be addressed.

UR - http://www.scopus.com/inward/record.url?scp=0035525020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035525020&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 609

EP - 619

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 5

ER -